The evolving role of aromatase inhibitors in breast cancer

@article{Mokbel2002TheER,
  title={The evolving role of aromatase inhibitors in breast cancer},
  author={K. Mokbel},
  journal={International Journal of Clinical Oncology},
  year={2002},
  volume={7},
  pages={0279-0283}
}
  • K. Mokbel
  • Published 2002
  • Medicine
  • International Journal of Clinical Oncology
Abstract. Anti-aromatase agents inhibit the cytochrome P-450 component of the aromatase enzyme complex responsible for the final step of estrogen biosynthesis in peripheral tissues. These drugs can be classified into first-generation (e.g., aminoglutethimide), second-generation (e.g., formestane and fadrazole), and third-generation (e.g., anastrozole, letrozole, and exemestane) agents. Anti-aromatase agents can also be divided into type I and type II inhibitors. Type I inhibitors have a… Expand
Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
  • I. Ahmad, Shagufta
  • Chemistry, Medicine
  • European journal of medicinal chemistry
  • 2015
TLDR
This review highlights the synthetic steroidal and nonsteroidal aromatase inhibitors reported in the literature in the last few years and will aid medicinal chemists in the design and synthesis of novel and pharmacologically-potent aromat enzyme inhibitors for the treatment of breast cancer. Expand
History of aromatase: saga of an important biological mediator and therapeutic target.
TLDR
The saga of these studies of aromatase and the ultimate utilization of inhibitors as highly effective treatments of breast cancer and for use in reproductive disorders serves as the basis for this first Endocrine Reviews history manuscript. Expand
The role of aromatase and other oestrogen producing enzymes in mammary carcinogenesis
TLDR
This chapter sheds light on CYP19 gene expression, aromatase enzyme activity and its role in mammary carcinogenesis, which is crucial to the development of new endocrine preventative and therapeutic strategies in postmenopausal females with hormonedependant breast cancer. Expand
THE ROLE OF AROMATASE AND OTHER IN MAMMARY CARCINOGENESIS
TLDR
Light is shed on CYP19 gene expression, aromatase enzyme activity ducing enzymes and their role in breast cancer development are these enzymes is crucial to the development of new endocrine preventative and therapeutic strategies in postmenopausal females with hormonedependant breast cancer. Expand
AROMATASE ENZYME: A REVIEW
TLDR
Lowering the estrogen level in post-menopausal women using Aromatase inhibitors has been proven to be effective in breast cancer treatment. Expand
The role of aromatase and 17-β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer
TLDR
This study shows that higher levels of the enzymes responsible for the local biosynthesis of estrogens especially aromatase are associated with a poor clinical outcome in patients with breast cancer. Expand
Aromatase inhibitors: Role in postmenopausal breast cancer.
TLDR
This study highlights the aromatase inhibitors reported in the current literature as well as the recent advances in the management of breast cancer. Expand
Oestrogen producing enzymes and mammary carcinogenesis: a review
TLDR
The role of CYP19 gene expression and aromatase activity in mammary carcinogenesis is highlighted and the important role of both STS and 17-β-HSD type 1 in local oestrogen production provides novel potential targets for endocrine therapy. Expand
Synthetic isoflavones and doping: A novel class of aromatase inhibitors?
TLDR
The preliminary in vitro results indicate that, in principle, a sufficiently large intake of isoflavones could alter the kinetics of the dynamic equilibria between androgens and estrogens, suggesting their monitoring in doping control routine analysis. Expand
Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors.
TLDR
Comparative quantitative structure-activity relationship (QSAR) study of steroidal aromatase inhibitors (SAIs) have been discussed in details to get an insight into the structural and physicochemical properties of SAIs controlling the aromatases inhibitory activity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
TLDR
Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival, and offers longer disease control in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-oestrogens. Expand
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
TLDR
The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens. Expand
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
  • M. Ellis, A. Coop, +9 authors M. Borgs
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
It is suggested that ErbB-1 and Erb B-2 signaling through ER is ligand-dependent and that the growth-promoting effects of these receptor tyrosine kinases on ER+ breast cancer can be inhibited by potent estrogen deprivation therapy. Expand
The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer.
TLDR
No significant change in either the extent of the conversion of androstenedione to oestrone or the production rate of oestrones was found when the postmenopausal women were re-investigated 2–3 months after ovariectomy and hysterectomy. Expand
Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age.
TLDR
The results of these studies demonstrate that with advancing age, there is a progressive and highly statistically significant increase in the efficiency with which circulating androstenedione is converted to estrone. Expand
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
TLDR
ExE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen. Expand
Endogenous hormones and breast cancer risk.
TLDR
The lack of total consistency among studies that have assessed estrogen differences, whether in breast cancer patients versus controls or in subgroups of the population characterized by different risk profiles for breast cancer, is not unexpected given the extraordinarily complex methodological issues that must be addressed in these studies. Expand
Recent Advances in Breast Cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001)
TLDR
The preliminary results of the ATAC study have shown that Arimidex is superior to tamoxifen in postmenopausal women with ER-positive early breast cancer in terms of DFS, adverse effects and prevention of contralateral breast cancer. Expand
Endocrine factors in endometrial carcinoma. A preliminary report.
TLDR
The findings support those of Corscaden, Fertig, and Gusberg that obesity and infertility are statistical concomitants with endometrial carcinoma but contradict current belief that there is direct evidence of abnormal endocrine state. Expand
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
TLDR
It is indicated that anastrozole should be considered as first-line therapy for postmenopausal women with advanced breast cancer because it satisfied the predefined criteria for equivalence to tamoxifen. Expand
...
1
2
...